From a cohort of human T-cell lymphotropic virus type I (HTLV-I) exposed transfusion recipients (N = 71) enrolled in the Jamaican Transfusion Study, 11 were selected for detailed laboratory evaluation. All recipients were followed at monthly intervals for 6 months and then bimonthly up to 1 year for evidence of HTLV-I seroconversion. Without regard to results on screening assays, pretransfusion and posttransfusion samples were tested with two licensed HTLV-1 wholevirus screening enzyme immunoassays (EIAs), recombinant ElAs for antibody against tax (p40x) and p21e envelope, standard whole virus Western blot (WB), WB enhanced with recombinant p21e. and radioimmunoprecipitation assay (RIPA). In the early period posttransfusion, antibody to gag core protein was predominant with anti-p24 generally appear-PIDEMIOLOGIC and experimental data have shown E that human T-cell lymphotropic virus type.1 (HTLV-I) is efficiently transmitted from infected blood donors to recipients by transfused cellular blood components.' Exposed recipients have the potential to spread the virus to sexual contacts and to their children via breast feeding.2-4 HTLV-I has been etiologically linked to adult T-cell leukemia/lymphoma (ATLL) and with the chronic neurodegenerative disorder, HTLV-I-associated myelopathyhropical spastic paraparesis (HAM/TSP).'.' The latter syndrome, HAMRSP, has been associated with a prior history of blood transfusion in Japan.8 As a result, blood bank donor screening for antibody to HTLV-I has become established policy in Japan and the United States and is under strong consideration in many other countries.
that a repeatably reactive EIA screening test be confirmed with more specific serologic tests, eg, Western blot (WB) and/or radioimmunoprecipitation assay (RIPA), which are capable of identifying antibody to two gene groups of the HTLV-I viral genome, namely, core p24 (gag) and envelope (env).y"o In this study, the dynamic process of HTLV-I antibody development in a prospectively followed cohort of transfusion recipients affords the opportunity to examine the detection of early immune response to HTLV-I infection associated with blood transfusion acquired infection.
MATERIALS AND METHODS
Study population. The Jamaican Transfusion Study was conducted between May 1987 and September 1988, before FDA licensure of an HTLV-I screening assay, to assess the seroprevalence of HTLV-I among blood donors in Kingston, Jamaica, an HTLV-I endemic area. In addition, to study the laboratory and clinical manifestations of transfusion-associated HTLV-I infection, pretransfusion HTLV-I antibody-negative recipients transfused with retrospectively identified seropositive donor units, had serial serum samples and clinical examinations obtained at monthly intervals for 6 months and then bimonthly intervals up to 1 year of follow-up or death from underlying disease. A total of 71 exposed transfusion recipients were enrolled in the study. The subset of recipients (N = 11) chosen for this laboratory analysis had completed 1 year of follow-up or had died, precluding further follow-up as of December 1988. All recipients were voluntarily enrolled and informed consent was obtained. The study was undertaken by the National Cancer Institute (NCI) in collaboration with the Jamaican Ministry of Health, National Transfusion Service, and the University of the West Indies in Kingston. This study was approved by the protocol review and human subjects' review committees at the respective institutions.
Laboratory methods. All sera were separated and stored at -70°C on site in Jamaica until shipment to NCI and subsequently to laboratory collaborators for testing. Antibodies to HTLV-I were detected with licensed whole-virus screening EIAs from two manufacturers (Abbott Laboratories, Chicago, IL and DuPont, Wilmington, DE) at independent testing laboratories. Infected HUT-102 cell lines served as the source of HTLV-I viral antigen in both EIAs. The procedures were performed according to the manufacturers' instructions. A recombinant tax (p4Ox) EIA (Abbott Laboratories) was performed. WB and RIPA confirmatory 896 Blood, Vol77, No 4 (February 15), 1991: pp [896] [897] [898] [899] [900] [901] [902] [903] [904] [905] For personal use only. on November 15, 2017 . by guest www.bloodjournal.org From
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assays were performed on all available samples without regard to previously identified reactivity by the screening EIAs, so that evaluation of early antibody patterns could be assessed. WB and RIPA were performed at Abbott Laboratories using whole virus from HUT-102 and DA202 cell lines. Several confirmatory assays currently under development also were used. A recombinant envelope EIA (env EIA) (Cambridge Bioscience, Worcester, MA) was performed according to the manufacturer's instructions. A modified WB (rec WB) using a recombinant envelope protein in conjunction with native viral proteins was performed at Biotech Laboratories, Rockville, MD. Both recombinant envelope assays used the p21e transmembrane glycoprotein (GP). Polymerase chain reaction (PCR) was performed on samples of several recipients to identify presence of early HTLV-I infection in the presence of weak or absent antibody reactivity. HTLV-antibody positive asymptomatic carriers from other Jamaican populations were evaluated by PCR for presence of HTLV-I and HTLV-I1 in a separate analysis. Peripheral blood (PB) lymphocytes of subjects were analyzed by the 3zP-oligonucleotide endlabeling technique described by Lee et al." Five oligonucleotide primer pairs were used including one tux (SK43-44) primer pair that corresponded to conserved sequences in both HTLV-I and HTLV-11, two protease primer pairs, and two LTR primer pairs unique to HTLV-I or HTLV-I1 with the ability to distinguish between these viruses. All 56 samples, including case 4 from this study, which were HTLVantibody reactive were HTLV-I, not HTLV-I1 (Dr G.M. Shaw, manuscript in preparation). Therefore, for the purpose of this study, antibody reactivity most likely represents HTLV-I. Exposure status of the recipients was not known by laboratory personnel, and all sera were coded and tested in a blinded fashion. In addition, sera from unexposed transfusion recipients were also included in test panels as a negative comparison group.
As defined by the PHS, samples were considered serologically confirmed for HTLV-I if antibodies against the gag (p24) and env (gp46, gp61168) gene products were present by WB or a combination of WB and RIPA?" Except as noted, this criteria was used as the 'gold standard' for defining serologic positivity.
A comparison of patterns of reactivity for each assay on all samples was performed. Subsequently, based on the PHS two gene group specifications, evaluation of combinations of the recombinant env EIA and WB (anti-p24 present), recombinant env EIA and the screening EIAs (EIA1 or EIA2 reactive), and the recombinant envelope WB alone (positive if anti-p24 plus anti-p2le present) were evaluated looking specifically at recipients who were considered to be seroconverters. A time-dependent analysis was performed on seroconverters with persistent antibody positivity for Diagnostic criteria.
greater than 6 months, or in the instance where follow-up was shorter, PCR positivity on PB lymphocytes was required. We excluded two potential seroconverters who had short follow-up because of death from underlying disease and on whom no PCR results were available, and one seroconverter who had evidence of reactivity on a pretransfusion sample, suggesting presence of seroconversion that probably was unrelated to transfusion.
Frequency computations were performed with SAS (Statistical Analysis System Institute, Cary, NC). Sensitivity is the proportion of samples positive by a specific assay and also positive with the reference standard as defined by the PHS guidelines with presence of antibody to gag and env by WB and/or RIPA. Specificity (negative by the specific assay and negative with the reference standard) could not be assessed in this population because of the bias in selecting the 11 HTLV-I-exposed recipients reported in this study. Ninety-five percent confidence intervals (CI) for proportions were calculated using the standard method for binomial distributions." The CI (lower limit, upper limit) gives the lowest and highest proportion compatible with the sample size.
Statistical analysis.
RESULTS
Recipient characteristics.
Recipients were patients hospitalized at Kingston, Jamaica, area hospitals whose diagnoses and indications for transfusion are listed in Table 1 . All seroconverters received cellular blood components (whole blood, packed red blood cells [RBCs] , platelets). In three cases, apparent passive transfer of antibody was suggested as evidenced by early reactivity with subsequent loss of antibody positivity. Among multiply transfused recipients who subsequently seroconverted after receiving an HTLV-I-contaminated unit, the antibody-negative pretransfusion samples indicated that seroconversion was temporally related to receipt of an antibody-positive unit. Unexposed transfusion recipients (N = 50) transfused with HTLV-I-antibody-negative donor units did not seroconvert (ref 13 and manuscript in preparation).
In Table 2 are listed serial test results for the eight seroconverters and the three nonseroconverters reported in this study. Both screening EIAs gave similar reactivities at the various time points. EIAl tended to be reactive at an earlier time point than EIA2 but this reactivity often did not signal positivity by WB and RIPA as defined by PHS criteria. The recombinant envelope EIA tended to score positive more often than Pattems of seroconversion. either whole-virus EIA, but discordant samples frequently were not positive by PHS criteria. WB and/or RIPA are the assays most often relied upon to detect core (gag) and envelope antibodies ( Fig 1A) . As shown in Fig 1A and summarized in Table 2 , antibody to core dpag) antigens consistently was recognized earlier than gp61/68 on RIPA. Of the gag antigens, anti-p24 was most often detected before or synchronous with anti-pl9, al- For though anti-pl9 developed before anti-p24 in case 7. An experimental WB (Fig 1B) adds a recombinantly produced antigen (p21e) from the transmembrane portion of the envelope to a conventional WB format. In three recipients anti-p2le was the only reactivity detected at the earliest time point posttransfusion. However, in two other recipients, there was evidence of pretransfusion reactivity. Case 8 had anti-pl9 reactivity on standard WB as well as anti-pl9 and anti-p2le on recombinant WB, suggesting seroconversion that was probably unrelated to transfusion. Case 9 had anti-p2le reactivity alone with all other assays showing no reactivity. In all other cases, anti-p2le was detectable in conjunction with either anti-p24 alone or anti-pl9 and anti-p24. As shown in Fig 1A and B , the intensity of bands increases over time during seroconversion and this strength of reactivity is supported by a pattern of increasing antibody titers over time (data not shown).
There was relative concordance between anti-p2le in the recombinant WB system compared with reactivity in the recombinant envelope EIA. Recombinant WB anti-p2le reactivity was detected in six seroconversion samples while reactivity in the recombinant envelope EIA was lacking. In four of these six samples, anti-p24 and/or anti-pl9 reactivity was detected. Only two of these six samples had corresponding envelope reactivity on RIPA.
Tax antibody with the recombinant p4Ox EIA was less frequently detected than either the gag or env reactivities. In occasional samples (case 8 and 9), anti-tax was detected synchronous with anti-gp46. However, in most instances, anti-tax was a late-appearing antibody usually occurring when all other assays were positive.
Case 4 presented an unusual pattern, with neither whole-virus EIA detecting samples consistently despite seropositivity as determined by WE? and RIPA reactivity.
This case, a bladder cancer patient with severe disability, illustrates the pattern observed in an exposed individual with low antibody titer and a poor immunologic response undoubtedly related to his advanced-stage bladder cancer. The presence of HTLV-I was confirmed in this case by PCR analysis performed on the day 133 sample with HTLV-Ispecific probes.
Thus, of the eight patients with sustained antibody response to HTLV-I, antibody to core antigens was detected earlier than envelope in the WB and RIPA systems using whole-virus lysate as antigen source. However, the addition of recombinant env antigens tended to enhance detectability of envelope resulting in both gag and recombinant env antibody reactivity occurring synchronously.
Cases 9 through 11 are unusual in that reactivity, initially present following an apparent seroconversion, disappeared by 6 to 9 months. Case 9 received fresh frozen plasma and was clearly strongly positive by all tests except the recombinant env EIA, but reactivity disappeared by 208 days. It is noteworthy in this case that antibody reactivity on visual review of the serial WBs and RIPAs was of greatest intensity at day 45; however, this intensity became increasingly faint by day 180 and absent thereafter. The recombinant env EL4 was negative except for one data point at day 180, while anti-p2le on WB was detectable through day 153. Given the observation in the seroconversion samples that anti-p2le was usually detectable before anti-gp61168, this reversal of the usual pattern suggests that antibody repertoire and affinity or differential metabolism of the passive antibody may influence the relative sensitivity of various assays to detect antibody.
In case 11, a recipient of packed RBCs, the pattern was reactivity to anti-p2le on the recombinant envelope WB and in the recombinant envelope EIA past 390 days in the absence of either anti-gp46 or anti-gp61168, and at many points without gag reactivity, si;ggests false reactivity as supported by a negative PCR result on day 69. However,
-PI9 -p21, rec viral infection can not be ruled out until antibody and PCR data after longer follow-up is obtained. Case 10, also a recipient of packed RBCs, had only transient reactivity to anti-pl9 and anti-p24 only at day 39 in one assay. In cases 9 and 11, the whole virus EMS were able to detect seropositivity, and it is noteworthy that these EIAs were negative for 3 months in samples that were persistently positive by WB and RIPA. In the other case, the whole-virus EIA and RIPA were negative at all time points. For cases 9, 10, and
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To determine early HTLV-I antibody patterns, a subset of the patients (N = 5 ) with serial samples (N = 44) obtained at monthly intervals who were persistently positive for greater than 6 months ( Table 2 , cases 3 and 5 through 7) or with more limited follow-up but known to be PCR positive ( Table 2 , case 4) were analyzed. Tests with the new assays, the recombinant envelope EIA and recombinant envelope WB, were performed and comparisons were made with the PHS criteria (two gene groups present with WB and/or RIPA). In addition, direct comparisons using combinations of the new assays with existing assays currently in use were performed to approximate the two gene group PHS criteria. Figure 2A shows results comparing two commercially available whole-virus EIAs, env EIA and tux p40x EIA ability to detect HTLV-I antibody. At 0 to 2 months posttransfusion, 20% and 10% of the samples were EIAl and EIA2 reactive, respectively. None of the samples were positive by the p4Ox EIA. Sixty percent of the samples were positive with the env EIA alone. Combining the screening whole-virus EIAs with env EIA to approximate the two gene group PHS criteria yielded 20% of the samples positive with the two methods in concordance with a rate of 20% of samples by PHS confirmation criteria (PHS CONF) (WB and/or RIPA). At 3 to 6 months posttransfusion, 95% of samples were EIAl reactive, 74% of samples were EIA2 reactive, 95% of samples were env EIA reactive, and 95% (95% CI 85%, 100%) of samples were reactive with the combination of the screening EIAs and env EIA compared with 74% (95% CI 54%, 94%) confirmed by PHS CONF. Sixteen percent of samples were p4Ox EIA reactive. By 7 to 14 months posttransfusion, 100% of the samples were positive by all methods except p4Ox EIA reactivity, which was 73%. Figure 2B summarizes results using the standard WB and the recombinant envelope EIA on the same samples presented in Fig 2A. At 0 to 2 months posttransfusion, anti-pl9 on WB was present in 40% (95% CI 12%, 74%) of the samples, anti-p24 on WB in 60% (95% CI 26%, 88%) of the samples, anti-gp46 on WB in none of the samples, and env EIA reactivity in 60% (95% CI 26%, 88%) of the samples. The combination of WB (anti-p24 present on WB) and env EIAwas reactive in 40% (95% CI 12%, 74%) of the samples at a time when only 20% (95% CI 3%, 55%) of the samples were PHS confirmed. At 3 to 6 months posttransfusion, 95% of samples had anti-pl9 and anti-p24 reactivity, 16% of samples had anti-gp46 reactivity, 95% of samples were env EIA reactive, and 90% (95% CI 77%, 100%) of samples were reactive with the combination of the WB and env EIA compared with 74% (95% CI 54%, 94%) confirmed by PHS criteria. By 7 to 14 months posttransfusion, 100% of the samples were positive by all methods except anti-gp46 reactivity on WB, which was detectable in only 60% of samples. Figure 2C presents results on the same recipients using HTL V-I antibody detection during seroconversion.
the recombinant envelope WB. At 0 to 2 months posttransfusion, anti-pl9 was present in 50% (95% CI 19%, 81%) of the samples, anti-p24 in 60% (95% CI 26%, 89%) of the samples, anti-p2le (transmembrane envelope protein) in 100% of the samples, and anti-gp46 in none of the samples.
Combining the presence of anti-p24 and anti-p2le on the rec WB to approximate the two gene group PHS criteria showed that 60% (95% CI 26%, 89%) of the samples were positive compared with 20% (95% CI 3%, 55%) of the samples by PHS criteria. At 3 to 6 months posttransfusion, 95% of samples had anti-pl9 and anti-p24 reactivity, 100% were anti-p2le reactive, 16% of samples had anti-gp46 reactivity, and 95% (95% CI 85%, 100%) of samples were both anti-p24 and anti-p2le reactive compared with 74% (95% CI 54%, 94%) of the samples by PHS criteria. By 7 to 14 months posttransfusion, 100% of the samples were positive by all methods except anti-gp46 reactivity on the rec WB, which was 67%.
DISCUSSION
Detection and confirmation of HTLV seropositivity is complex, not only because of the relatively low titers of antibodies compared with human immunodeficiency virus (HIV), but also because of the difficulties in defining viral infection in different populations because of related viruses (eg, HTLV-I v HTLV-11) with shared cross-reactive antigen~.'~.'' The current study was undertaken in Jamaica where extensive surveys of HTLV seropositives have confirmed the absence of HTLV-I1 by PCR (G. Shaw, manuscript in preparation). Thus, the current study not only clarifies the natural history of early HTLV-I infection, but also affords an opportunity to define the performance characteristics of various HTLV-I antibody approaches for detecting and confirming reactivity.
The major antigenic structural genes of HTLV are core (also termedgug) of 24,000 (p24) and 19,000 (p19) molecular weight and envelope (env) composed of 21,000 (gp21) transmembrane and 46,000 (gp46) external envelope, which when complexed has a 61,000 to 68,000 (gp61168) molecular weight. The tux gene of HTLV regulates virus growth by promoting RNA message expres~ion.'~~'~ Thus, in a new productive infection, expression of tux for HTLV-I would be expected as an early event in viral gene expression to favor establishment of infection. Contrary to some studies that suggest that anti-tux should appear early in seroconversion as virus replication is promoted,2" in our study, anti-tux antibodies in most cases were not detected until much later in infection, usually at a time when RIPA could detect env, anti-gp61/68. It may be that the expression of this regulatory protein takes place in a way that avoids immune surveillance and that more direct measures such as PCR to search for viral RNA message would enhance our understanding of the role of HTLV-regulatory genes in early HTLV infection.
Antibody to p24 antigen was most frequently detected earlier than was antibody to p19 antigen with a few exceptions. However, in all cases the antibodies to both antigens were detectable within 30 to 60 days of each other. For personal use only. on November 15, 2017. by guest www.bloodjournal.org From This result suggests that either antigen may be indicative of HTLV-I infection when found in conjunction with antibody to envelope antigen. In the U.S. blood supply and among parenteral drug abusers, HTLV-I1 often confounds interpretation of results, because HTLV-I reagents often detect HTLV-I1 infection with a strong anti-p24 reactivity and a weak or absent anti-pl9 reactivity.*'
The envelope reactivity of HTLV-I is complicated. RIPA clearly detects the fusion protein (gp61/68) that represents the coupled external (gp46) and transmembrane (gp21) antigens. In the current study, a recombinant p21e protein often was detectable in conjunction with evidence of gag reactivity and, in some cases, in the absence of any other envelope reactivity. In the case of isolated anti-p2le reactivity (no gag present), particularly such as that observed in case 11 (Table 2) , it is probable that the persistent seropositivity observed in this case represents false positivity, a conclusion supported by the negative PCR result in this case. However, in most cases, anti-p2le reactivity was coincident with anti-pl9 and anti-p24, and with few exceptions in parallel with anti-gp61/68 reactivity. An instructive exception was case 9 in Table 2 , where a recipient of fresh frozen plasma with passive transfer of antibody had strong and persistent reactivity to gp61/68 on RIPA in the absence of reactivity to recombinant p21e. It is very possible that the contrast between seroconversion samples showing early anti-p2le reactivity with later development of anti-gp61/68 and anti-gp46 reactivity in fact represents a pattern of reactivity relevant to the virologic correlates of HTLV-I infection. It may be, as has been reported for HIV-1,"that the genetically more stable transmembrane envelope protein is more antigenic early in infection while the more labile external large envelope is less so. The observation that the external large envelope of HTLV-I is easily shed by the virus may support this concept. In fact, in establishing a new infection it may be advantageous for the virus if this extemal envelope, which contains the major neutralizing epitope of the virus, is more transparent to the host immune system.
We first evaluated all available samples with each assay without regard to previously identified reactivity from a screening assay. This procedure is in contrast to what would take place in a clinical setting, such as a blood bank, but we were able to obtain more information by using this approach because screening assays are less sensitive than confirmatory assays." Figure 2A Limitations of the standard WB are reflected in its inability to detect anti-gp46 envelope. The detection of the presence of anti-gp46 by WB is not very sensitive in the early period of seroconversion (Fig 2B and C ) . In fact, neither WB was able to detect anti-gp46 at 0 to 2 months. At 3 to 6 months there is some reactivity with gp46, but even after 7 to 14 months, when all other assays are loo%, anti-gp46 reactivity fails to reach maximum positivity. Only 34% of the samples meeting the PHS criteria were confirmed with the use of the WB alone (anti-p24 and anti-gp46 present). The remaining 66% of samples required the use of the technically complex, labor-and timeintensive RIPA for confirmation. The assays using the recombinant p21e transmembrane envelope antigen appear to be very sensitive during early infection. When anti-p2le is detectable with both anti-pl9 and anti-p24, we feel that it is safe to infer that p21e antibodies have virologic significance. The assays using recombinant p21e envelope antigen are, therefore, likely candidates to simplify the confirmatory process and potentially reduce the number of samples requiring RIPA for confirmation.
Although important time-dependent determinants of the antibody response can be assessed from this study, samples obtained in this manner also have limitations. Our ability to evaluate sensitivity is greatly enhanced, but the evaluation of the specificity (false-positive rate) of the assays can not be evaluated. This lacking is because of the fact that, given known exposure to HTLV-I, any reactivity may indicate passive transfer of antibody from the donor or newly acquired infection in the recipient. Nonetheless, the data from this study emphasize that test performance can be enhanced by increasing the level of viral antigens either by developing enhanced whole-virus expression systems or through judicious combinations of native and purified recombinant proteins.
